• Palladyne AI recently secured two U.S. Army contracts to research, develop, and operationally validate its SwarmOS and Gremlin-X systems with 4th Infantry Division warfighters, alongside integrating SwarmOS into the Army’s Next-Generation Command and Control ecosystem and showcasing capabilities at large-scale exercises like Northern Strike 26-2.
• By pairing these embodied AI and swarming validations with an exclusive U.S. production partnership for Israel Aerospace Industries’ HARPY, HAROP, and Mini HARPY loitering munitions, Palladyne AI is positioning its software and manufacturing stack directly against mission profiles the Department of War is actively resourcing.
• Next, we’ll explore how these new U.S. Army validation contracts for SwarmOS and Gremlin-X could reshape Palladyne AI’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Palladyne AI Investment Narrative Recap

To own Palladyne AI, you need to believe its embodied AI and loitering munitions stack can convert early defense validations into durable U.S. Department of War programs, despite ongoing losses and a high sales multiple. The near term catalyst is clear operational validation and follow on contracts for SwarmOS and Gremlin X with the U.S. Army, while the biggest risk remains execution slippage or budget timing shifts that delay scaling these platforms into larger production awards.

The June 17 U.S. Army contracts to research, develop and operationally validate SwarmOS and Gremlin X with 4th Infantry Division warfighters look most relevant here. They tie directly into earlier SwarmOS integration with the Army’s Next Generation Command and Control ecosystem, reinforcing the idea that Palladyne’s autonomy stack is being exercised inside the workflows its key customer is already using, which could influence how quickly future Army and Department of War opportunities take shape.

Yet investors should also understand how dependent this story is on Department of War priorities and what happens if those procurement plans shift or slow...

Palladyne AI's narrative projects $67.1 million revenue and $6.2 million earnings by 2028. This requires 149.0% yearly revenue growth and a $47.6 million earnings increase from $-41.4 million today.

Uncover how Palladyne AI's forecasts yield a $9.00 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Before this Army news, the most bullish analysts were modeling revenue to reach about US$71.2 million and earnings of roughly US$6.7 million by 2028, which is far more optimistic than the baseline view and leans heavily on faster contract conversion and execution than the risk that multiple new business models stretch management thin suggests.

Explore 5 other fair value estimates on Palladyne AI - why the stock might be worth just $7.00!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Palladyne AI research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Palladyne AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Palladyne AI's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.